These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 10215647

  • 1. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
    Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA.
    J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
    [Abstract] [Full Text] [Related]

  • 2. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P.
    Circulation; 2004 Mar 30; 109(12):1468-71. PubMed ID: 15037526
    [Abstract] [Full Text] [Related]

  • 3. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I.
    J Pharmacol Exp Ther; 1999 Aug 30; 290(2):551-60. PubMed ID: 10411562
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis.
    Takano T, Cybulsky AV, Cupples WA, Ajikobi DO, Papillon J, Aoudjit L.
    J Pharmacol Exp Ther; 2003 Apr 30; 305(1):240-9. PubMed ID: 12649375
    [Abstract] [Full Text] [Related]

  • 5. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
    Huledal G, Jonzon B, Malmenäs M, Hedman A, Andersson LI, Odlind B, Brater DC.
    Clin Pharmacol Ther; 2005 May 30; 77(5):437-50. PubMed ID: 15900289
    [Abstract] [Full Text] [Related]

  • 6. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
    Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M.
    Clin Pharmacol Ther; 1999 Jul 30; 66(1):76-84. PubMed ID: 10430112
    [Abstract] [Full Text] [Related]

  • 7. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA.
    J Clin Pharmacol; 2000 Dec 30; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [Abstract] [Full Text] [Related]

  • 8. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.
    Nüsing RM, Reinalter SC, Peters M, Kömhoff M, Seyberth HW.
    Clin Pharmacol Ther; 2001 Oct 30; 70(4):384-90. PubMed ID: 11673754
    [Abstract] [Full Text] [Related]

  • 9. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
    Tuleja E, Mejza F, Cmiel A, Szczeklik A.
    Arterioscler Thromb Vasc Biol; 2003 Jun 01; 23(6):1111-5. PubMed ID: 12730088
    [Abstract] [Full Text] [Related]

  • 10. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
    Kato S, Ogawa Y, Kanatsu K, Okayama M, Watanabe T, Arakawa T, Takeuchi K.
    J Pharmacol Exp Ther; 2002 Nov 01; 303(2):503-9. PubMed ID: 12388629
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats.
    Turull A, Piera C, Queralt J.
    Inflammation; 2001 Apr 01; 25(2):119-28. PubMed ID: 11321358
    [Abstract] [Full Text] [Related]

  • 13. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
    Praticò D, Tillmann C, Zhang ZB, Li H, FitzGerald GA.
    Proc Natl Acad Sci U S A; 2001 Mar 13; 98(6):3358-63. PubMed ID: 11248083
    [Abstract] [Full Text] [Related]

  • 14. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
    Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, Mehlisch DR, Gertz BJ.
    Clin Pharmacol Ther; 1999 Mar 13; 65(3):336-47. PubMed ID: 10096266
    [Abstract] [Full Text] [Related]

  • 15. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K.
    Clin Pharmacol Ther; 2002 Jul 13; 72(1):50-61. PubMed ID: 12152004
    [Abstract] [Full Text] [Related]

  • 16. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR, Sperling RS, Reicin A, Gertz BJ.
    Am Heart J; 2003 Oct 13; 146(4):591-604. PubMed ID: 14564311
    [Abstract] [Full Text] [Related]

  • 17. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial.
    Leese PT, Recker DP, Kent JD.
    J Clin Pharmacol; 2003 May 13; 43(5):504-13. PubMed ID: 12751271
    [Abstract] [Full Text] [Related]

  • 18. Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine.
    Llinás MT, López R, Rodríguez F, Roig F, Salazar FJ.
    Am J Physiol Renal Physiol; 2001 Nov 13; 281(5):F975-82. PubMed ID: 11592955
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.